1. Home
  2. TSAT vs ARVN Comparison

TSAT vs ARVN Comparison

Compare TSAT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telesat Corporation

TSAT

Telesat Corporation

HOLD

Current Price

$49.46

Market Cap

697.5M

Sector

Industrials

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.64

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSAT
ARVN
Founded
1969
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
697.5M
600.2M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
TSAT
ARVN
Price
$49.46
$7.64
Analyst Decision
Hold
Buy
Analyst Count
1
19
Target Price
★ $37.00
$15.05
AVG Volume (30 Days)
108.8K
★ 736.1K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 1.70
Revenue
N/A
★ $262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.58
Revenue Growth
★ N/A
N/A
52 Week Low
$23.01
$6.97
52 Week High
$61.54
$14.22

Technical Indicators

Market Signals
Indicator
TSAT
ARVN
Relative Strength Index (RSI) 53.90 32.15
Support Level $48.11 N/A
Resistance Level $52.11 $9.69
Average True Range (ATR) 2.82 0.35
MACD 0.06 -0.12
Stochastic Oscillator 57.31 13.33

Price Performance

Historical Comparison
TSAT
ARVN

About TSAT Telesat Corporation

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: